Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates
Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis measles virus vector-based platform.
- Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis measles virus vector-based platform.
- We are excited to collaborate with MSD and to develop a vaccine that has the potential to provide a significant benefit to a great number of patients worldwide.
- Under the terms of the agreement, Themis will develop vaccine candidates against an undisclosed disease target.
- MSD will provide research funding and make an equity investment in Themis.